Pd-L1 + Macrophages Are Associated With Favorable Features in Primary Mediastinal (Thymic) Large B-Cell Lymphoma

Authors

Raphael E Steiner
Edwin R Parra
Francisco Vega
Lei Feng
Jason R Westin
Sattva S Neelapu
Paolo Strati
Michael R Green
Christopher R Flowers
Luisa M Solis
Ignacio I Wistuba
Sairah Ahmed
Ranjit Nair
Fredrick B Hagemeister
Mansoor Noorani
Mario L Marques-Piubelli

Publication Date

3-20-2023

Journal

Experimental Hematology & Oncology

Abstract

Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a rare, aggressive subtype of non-Hodgkin lymphoma and has a complex inflammatory microenvironment. Although most patients can be cured with standard-of-care immunochemotherapy, patients who have disease relapse have an unfavorable prognosis. Pre-treatment prognostic biomarkers in PMBCL are needed. In this retrospective study, we analyzed the clinical features and outcomes of PMBCL patients and their association with immune cell subpopulations identified by multiplex immunofluorescence at initial diagnosis. Two different antibody panels were used to assess macrophages in tissue biopsy specimens collected before the initiation of induction therapy. Twelve PMBCL patients, including five patients who had disease relapse, were included in the analysis. At a median follow-up time of 32.2 months, the median progression-free and overall survival durations were not reached. Our findings suggest that a high density of PD-L1

Keywords

Primary mediastinal large B-cell lymphoma, Macrophages, PD-L1, CD30, Biomarker

Comments

Associated Data

PMID: 36941707